Akebia Therapeutics, Inc. Blog | Talkmarkets

Latest Posts

Research Report: Akebia Therapeutics, Inc.

Article By: Elle Investments

Saturday, April 20, 2019 3:11 PM EDT

As of 4Q18, AKBA had cash of $322M. Additionally, AKBA is eligible to receive over $150M in development and regulatory milestones from its collaboration partners.

In this article: AKBA

Read

Akebia Therapeutics, Inc. Shares Shoot Up On Announcement Of Collaboration With Otsuka

Article By: TickerTV

Wednesday, April 26, 2017 8:45 AM EDT

AKBA opened trading yesterday at $9.38 which was up from the previous day’s trading close of $9.31. Shares closed trading yesterday at $9.37 and spiked up after market to $12.25, equivalent to a 31% increase from the closing price.

In this article: AKBA

Read

Seven Biotech Names On The Upswing: 2016 Small-Cap Biotech Watchlist Update

Article By: The Life Sciences Report

Wednesday, March 9, 2016 5:47 PM EDT

Biotech stocks—and the stock market in general—took a dive at the beginning of 2016, headed down on macroeconomic factors such as financial instability in China.

In this article: SGYP, CRMD, ORMP, SRNE, ARRY, PTIE, AGEN, GALE, PPHM, EVOK, ADMA, AKBA, KPTI, VSTM, AST, RXDX, AGTC, WVE, FATE, FLKS, PIRS, ABEO

Read

The 2016 Small-Cap Biotech Watchlist Debuts At The Biotech Showcase

Article By: The Life Sciences Report

Wednesday, January 27, 2016 6:16 PM EDT

This may prove a challenging year for small-cap biotechs, but the five analysts who selected companies for inclusion on The Life Sciences Report's 2016 Small-Cap Biotech Watchlist believe these companies have a good producing value for investors.

In this article: AZN, NVO, SGYP, SNY, CRMD, ORMP, CMXHY, SRNE, ALNY, ARRY, INCY, IRWD, PTIE, REGN, VRTX, AGEN, GALE, GRFS, PPHM, EVOK, ADMA, AKBA, VSTM, AST, RXDX, AGTC, NK, WVE, FATE, FLKS

Read